Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
02/10/17Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the compensation committee of Alnylam's board of directors, which is composed entirely of independent directors, approved a grant, effective as of February 6, 2017, to a vice president level employee of the Company, of a non-qualified stock option to purchase 50,000 shares of Alnylam's common s... 
Printer Friendly Version
02/07/17Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 pm ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investor... 
Printer Friendly Version
02/02/17Alnylam Presents New Data on Fitusiran at EAHAD
– New Phase 1 Results Demonstrate Effective Bleed Management with Replacement Factor and Bypassing Agents During Fitusiran Administration – – Stability Study Results Support a Greater than Two Year Product Shelf-Life at Room Temperature Storage Conditions – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company today announced new results from... 
Printer Friendly Version
02/01/17Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February 8, 2017, after the U.S. financial markets close. Management will provide an update on the company and discuss fourth quarter and year-end 2016 results as well as expectations... 
Printer Friendly Version
01/03/17Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its present... 
Printer Friendly Version
01/03/17Alnylam Announces Management Change and Key Promotion
– Company Announces Departure of Chief Business Officer and Promotion of Pushkal Garg, M.D., to Chief Medical Officer – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that David-Alexandre "DA" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the company for personal reasons. His resignation will be effective... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.